Regular follow-up should include assessment of weight loss trajectory, tolerability, medication adherence, and renal function if significant GI symptoms occur
Semaglutide or Tirzepatide, cannot be prescribed and should not be purchased by individuals with a BMI under 25, an eating disorder, diabetes, gallbladder disease, history of drug or alcohol abuse, recent bariatric surgery, pancreatitis, medullary thyroid cancer or a family history of it, diabetic retinopathy, multiple endocrine neoplasia type 2, or those who are pregnant, breastfeeding, or planning to become pregnant
Unlike anabolic steroids, it stimulates your own pituitary rather than replacing GH exogenously, which makes long-term use more feasible
Final Thoughts Tirzepatide and Mounjaro are not competing products